Background: After first-line antiretroviral therapy failure, the importance of change in nucleoside reverse transcriptase inhibitor (NRTI) in second line is uncertain due to the high potency of protease inhibitors used in second line.
INTRODUCTION
Although drug resistance is rare at antiretroviral therapy (ART) initiation, most patients who fail first-line ART have some resistance to nucleoside reverse transcriptase inhibitors (NRTIs) that are also used in second-line regimens. [1] [2] [3] [4] [5] [6] To optimize the efficacy of NRTIs in second line, national treatment guidelines in South Africa and Zambia recommend patients change at least 1 NRTI when switching to second line. [7] [8] [9] [10] [11] In practice, changing NRTIs does not always occur, usually due to contraindications to specific NRTIs or lack of availability.
The importance of the choice of NRTIs used in second-line is questioned because of the high potency of standard protease inhibitors (PIs) that are a part of second-line regimens (lopinavir/ritonavir). Second-line ART can successfully suppress HIV in the presence of NRTI drug resistance mutations [12] [13] [14] [15] [16] [17] ; yet, the number of NRTIs switched from first-to second-line ART is associated with improved outcomes on second line. 18 We investigated the impact of switching NRTIs on virologic and immunologic outcomes as patients in South Africa and Zambia reach multiple years on second line.
METHODS
We used data from the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) cohort, a National Institutes of Health-funded initiative pooling data to address HIV treatment research questions. IeDEA-SA data included medical records from 2004 to 2013 from 175,933 patients in Zambia and 79,908 patients in South Africa, with information on basic patient demographics, height, weight, date of visits, diagnoses, ART drugs, and laboratory values, including CD4 and, in South African sites, HIV viral load.
The study population included adult patients aged 18 years and older, initiated on standard first-line ART [2 NRTIs plus a non-NRTI], and had evidence of first-line failure: either a viral load .1000 copies/mL among South African patients after at least 6 months on treatment, or 2 consecutive CD4 counts ,100 or a 30% drop from highest CD4 count among Zambian patients. The first NRTI used in first line and second line was categorized into zidovudine (AZT), stavudine (d4T), tenofovir (TDF), abacavir (ABC), or other. We evaluated switch to each type of NRTI for patients: (1) initiated on AZT, (2) initiated on d4T, and (3) initiated on TDF.
Treatment failure on second line was our primary outcome and was modeled with crude and propensity scoreadjusted Cox proportional-hazards regression where propensity score was included in the models as a covariate. Our primary analysis used data from South Africa, where viral load monitoring was available, and treatment failure was defined as 2 consecutive viral loads .1000 copies/mL. We also evaluated immunologic failure on second-line ART in Zambia, where treatment failure was persistent CD4 levels below 100 cells/mm 3 , defined as 2 consecutive CD4 counts ,100 cells/mm 3 . 19, 20 Potential confounders included year of starting second line, age, sex, duration on first line, and firstline non-NRTI, as well as CD4 count, viral load, hemoglobin, and creatinine clearance at first-line initiation and at switch to second line. Multiple imputation was used for missing covariates unless they were missing for .50% of patients. 21, 22 Propensity scores for switching to each type of NRTI vs. remaining on the same NRTI were calculated for each model with logistic regression, which allowed us to control for as many confounders as possible while maximizing statistical efficiency. 23 For South African models, propensity scores were adjusted for year of switch to second line, sex, age, baseline alanine aminotransferase, hemoglobin, CD4, creatinine clearance, weight, and viral load and CD4 count at time of switch to second line. Models for changing from TDF were not adjusted for year because it was only available in more recent years. For Zambian models, propensity scores were adjusted for year of switch to second line, sex, age, baseline alanine aminotransferase, CD4, hemoglobin, weight, creatinine clearance, and second-line values of CD4, creatinine clearance, and hemoglobin. Models for changing from d4T were not adjusted for year because the number initiated on d4T who remained on d4T in second line was too small and propensity score models did not converge when year was adjusted. In sensitivity analyses, we adjusted for loss to follow-up through inverse probability of treatment weighting. 24 
RESULTS

Study Sample
In South Africa, 4614 patients had evidence of first-line virologic failure and switched to a PI-based regimen and in Zambia, 2061 patients experienced first-line immunologic failure and switched to a PI-based regimen. Patients without visits after date of switch to second line (2.5%) and patients who did not have any NRTI identified in the regimen at time of second-line initiation (3.2%) were excluded. The total sample included 6290 patients (4275 in South Africa and 2015 in Zambia).
Among the 6290 patients in analysis, the majority were female (61%) and the median age was 34 years [interquartile range (IQR): [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . A description of the patients is shown by country and by change in NRTI in second line in Supplemental Digital Content Table 1 , http://links.lww.com/ QAI/B107. In both countries, CD4 counts at ART initiation were low (median ,100 cells/mm 3 ), and CD4 count at switch to second line was slightly lower for patients who had a change in second-line NRTI in South Africa, but not in Zambia (Supplemental Digital Content Table 1 , http://links. lww.com/QAI/B107). Overall, 90% of patients changed NRTIs at second line (Table 1) . In South Africa, the 
Second-Line Outcomes
Propensity score-adjusted Cox proportional-hazards models for virologic failure in South Africa are shown in Table 2 (summary of propensity scores displayed in Supplemental Digital Content Table 2 , http://links.lww.com/QAI/ B107). Among patients initiated on AZT, we observed an association between switching to TDF and reduced secondline failure compared with staying on AZT {adjusted hazard ratio [aHR] 0.25 [95% confidence interval (CI): 0.11 to 0.57]}. Switching from AZT to ABC was not associated with reduced failure. Among patients initiated on first-line d4T, there was weak evidence for reduced hazards of failure on second line associated with switching to TDF vs. remaining on d4T [aHR = 0.70 (95% CI: 0.42 to 1.16)]. Switching from d4T to AZT did not have an association with reduced hazards of second-line failure. For patients initiating TDF in first line, follow-up time was more limited because the drug was introduced into South Africa's national program later than d4T and AZT. Changing to AZT in second line vs. remaining on TDF was associated with decreased second-line failure (aHR: 0.35; 95% CI: 0.13 to 0.96). Although loss to follow-up was common (34% of patients), weighting models using inverse probability weights to account for loss to follow-up did not impact the hazard ratio point estimates.
Using patient data from Zambia to evaluate second-line immunologic failure showed similar trends, but all hazard ratio estimates had wide confidence intervals (Supplemental Digital Content Table 3 , http://links.lww.com/QAI/B107).
DISCUSSIONS
Among patients in South Africa who failed first-line ART and switched to second-line ART, change in NRTI was associated with reduced virologic failure on second line for changes to TDF and for change from TDF to AZT. Changes to other NRTIs had no association with second-line failure. In Zambia, where virologic monitoring was not available and treatment failure on second line was more poorly defined and likely underestimated, [25] [26] [27] [28] we did not see strong evidence of a benefit from changing NRTIs in second line.
It is possible that drug resistance to NRTIs had an effect on second-line failure; yet, previous research has shown that PI-based second-line ART can successfully suppress HIV in the presence of NRTI drug resistance mutations and that poor adherence is a more likely cause of second-line failure. [12] [13] [14] [15] [16] [17] 29 Given the importance of adherence, it is possible that patients on TDF in second line often had better outcomes because the drug was better tolerated. Interestingly, remaining on TDF in second line after initiating TDF in first line was common in Zambia, perhaps because of physician preference for this drug. This trend may explain why there was less switching of NRTIs in Zambia in recent years as TDF became available. We did not see any strong evidence for reduction in secondline immunologic failure associated with switching away from TDF in Zambia. Because most patients now initiate TDF-based regimens as first-line ART, further exploration into switching to AZT, which was associated with better second-line outcomes, compared with remaining on TDF in South Africa, is warranted.
AZT is no longer the preferred NRTI for first line in Zambia or South Africa; however, it may still be used for patients with contraindications to TDF (eg, renal failure). First-line AZT in South Africa would typically only have been prescribed over d4T (under 2004 guidelines) when patients had preexisting peripheral neuropathy or were at increased risk of hyperlactatemia. Since TDF became available in South Africa in 2010, patients normally are only initiated on AZT if they have renal failure. In Zambia, AZT was a more common option in first line, and was part of national guidelines before 2010, but has now also been replaced by TDF. Our results showed evidence that switching from AZT to TDF was associated with reduced second-line failure but the impact of switching from AZT to ABC was not clear. For patients initiated on AZT-based regimens because of renal failure, switching to TDF in second line may not be an option if contraindications remain, and more detailed research into treatment choices for this population is important.
One of the main obstacles in this study is the potential for confounding by indication, which is common in We did not see large differences in monitoring between these groups, but monitoring frequency did change over time, along with use of NRTIs in second-line regimens, with modifications to national treatment guidelines; so, we controlled for calendar time where possible. Finally, although we had a large initial sample size, stratification by NRTI used limited the numbers in the models, and with a relatively short follow-up time on second line, led to some imprecise results. Our results support that the NRTI in second line plays a role in second-line outcomes and provide limited evidence in support of current guidelines to change NRTI in second line, although the impact of NRTI on second-line activity may act through drug resistance, drug side effects, or better tolerance of drugs associated with improved adherence. This study supports the need for more research regarding NRTI choices for patients with renal failure who fail AZT first-line regimens, ideally with drug resistance data, and more followup of patients initiated on TDF who must switch to second line. Observational patient cohorts in South Africa and Zambia are challenging settings for answering these complex questions comparing prescription of different drugs, and more information from clinical trials is necessary.
